stockrow
Friday 6 November 2026
Export XNCR’s income statement to Excel — free account
Xencor, Inc.
XNCR Healthcare Biotechnology
Xencor, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $125.6 million, up 13.7% from fiscal 2024.
- Revenue
- +17.5%
- EPS
- +29.3%
- Free cash flow
- −52.9%
Quarter to June 2026, against a year earlier
36.33
2.28
+6.70%
Follow XNCR
Alert me
Xencor, Inc. (XNCR) EBITDA
Xencor, Inc.'s EBITDA for fiscal 2025 was −$170.5M, compared with −$180.0M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$209.4M. Over the past ten years it has ranged from −$180.0M (fiscal 2024) to $55.4M (fiscal 2021); the current reading is higher than 18% of that period. Xencor, Inc. ranks 515th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$170.5M | — |
| FY2024 | −$180.0M | — |
| FY2023 | −$133.2M | — |
| FY2022 | −$72.0M | — |
| FY2021 | $55.4M | — |
| FY2020 | −$70.7M | — |
| FY2019 | $14.0M | — |
| FY2018 | −$76.3M | — |
| FY2017 | −$37.9M | — |
| FY2016 | $47.9M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$34.6M | — |
| Mar 2026 | −$75.3M | — |
| Dec 2025 | −$54.5M | — |
| Sep 2025 | −$44.9M | — |
| 42 more quarters | Free account |
Against its own ten years
Low −$180.0M
High $55.4M
Ten-year median
−$70.7M
Current reading's percentile
18
EBITDA against peers
| Company | EBITDA |
|---|---|
| ADMA ADMA Biologics Inc compare | $232.8M |
| MBX MBX Biosciences, Inc. compare | −$117.7M |
| XNCR Xencor, Inc. | −$209.4M |
| PHVS Pharvaris N.V. compare | −$212.2M |
| NAMS NewAmsterdam Pharma Company N.V. compare | −$233.2M |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −$253.7M |
| BEAM Beam Therapeutics Inc. compare | −$381.7M |
| RXRX Recursion Pharmaceuticals, Inc. compare | −$421.1M |
| RCUS Arcus Biosciences, Inc. compare | −$488.0M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on XNCR
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement